GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) EBIT : ₦847 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria EBIT?

GlaxoSmithKline Consumer Nigeria's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was ₦123 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was ₦847 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GlaxoSmithKline Consumer Nigeria's annualized ROC % for the quarter that ended in Jun. 2023 was 13.43%. GlaxoSmithKline Consumer Nigeria's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 124.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GlaxoSmithKline Consumer Nigeria's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 36.37%.

GlaxoSmithKline Consumer Nigeria EBIT Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria EBIT Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

987.83

1,169.33

1,039.37

950.42

1,241.23

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial															285.83	233.39	198.80	524.87	123.45

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's EBIT

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Consumer Nigeria's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's EV-to-EBIT falls into.

GlaxoSmithKline Consumer Nigeria EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦847 Mil.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GlaxoSmithKline Consumer Nigeria's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	493.812 * ( 1 - 32.58% )	/	( (2759.369	+	2197.78)	/ 2 )
=	332.9280504	/	2478.5745
=	13.43 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29386.204	-	18469.964	-	( 18000.871	-	max(0, 19844.984	-	28001.855	+	18000.871	))
=	2759.369

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30268.016	-	20145.561	-	( 21203.332	-	max(0, 21053.574	-	28978.249	+	21203.332	))
=	2197.78

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

GlaxoSmithKline Consumer Nigeria's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	493.812	/	( ( (441.246 + max(-9980.369, 0))	+	(348.993 + max(-13546.008, 0)) )	/	2 )
=	493.812	/	( ( 441.246	+	348.993 )	/	2 )
=	493.812	/	395.1195
=	124.98 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3631.738	+	3739.54	+	2493.337)	-	(18469.964	+	0	+	1375.02)
=	-9980.369

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2997.004	+	2182.243	+	2328.319)	-	(20145.561	+	0	+	908.013)
=	-13546.008

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GlaxoSmithKline Consumer Nigeria's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	847.13	/	2329.029
	=	36.37 %

GlaxoSmithKline Consumer Nigeria EBIT Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines